Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ‐56914845 (GSK2336805) in subjects with hepatic impairment

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|55|9|1042-1050

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.9, 2015-09, pp. : 1042-1050

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GSK2878175, a pan‐genotypic non‐nucleoside NS5B polymerase inhibitor, in healthy and treatment‐naïve chronic hepatitis C subjects

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 1, 2018-01 ,pp. : 19-27

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection

By  

Reviews on Recent Clinical Trials, Vol. 9, Iss. 2, 2014-06 ,pp. : 115-123

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 58, Iss. 3, 2018-03 ,pp. : 357-363

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 12, 2015-12 ,pp. : 1011-1019

John Wiley & Sons Inc

Access to resources Recommend Favorite

Organic Anion Transporting Polypeptide‐Mediated Transport of, and Inhibition by, Asunaprevir, an Inhibitor of Hepatitis C Virus NS3 Protease

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 2, 2015-02 ,pp. : 159-166

John Wiley & Sons Inc

Access to resources Recommend Favorite